Applied Genetic Technologies Corporation
APPLIED GENETIC TECHNOLOGIES CORP (Form: 3, Received: 09/15/2017 17:09:08)
FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Feinsod Matthew

2. Date of Event Requiring Statement (MM/DD/YYYY)
9/5/2017 

3. Issuer Name and Ticker or Trading Symbol

APPLIED GENETIC TECHNOLOGIES CORP [AGTC]

(Last)        (First)        (Middle)

C/O APPLIED GENETIC TECHNOLOGIES CORP., 14193 NW 119TH TERRACE, SUITE #10

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                            _____ 10% Owner
___ X ___ Officer (give title below)          _____ Other (specify below)
Interim Chief Medical Officer /

(Street)

ALACHUA, FL 32615       

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed (MM/DD/YYYY)

 

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person


Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock   17648   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy)     (1) 7/31/2024   Common Stock   22500   $16.00   D    

Explanation of Responses:
(1)  Option became exercisable for 25% of the underlying shares on June 26, 2015, and thereafter became and will become exercisable for the remaining underlying shares in equal monthly installments over three years, resulting in the option being exercisable for 100% of the underlying shares on June 26, 2018.

Remarks:
Exhibit List
Exhibit 24 - Power of Attorney

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Feinsod Matthew
C/O APPLIED GENETIC TECHNOLOGIES CORP.
14193 NW 119TH TERRACE, SUITE #10
ALACHUA, FL 32615


Interim Chief Medical Officer

Signatures
/s/ Stacie Aarestad, Attorney-in-fact 9/15/2017
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

                               POWER OF ATTORNEY

     KNOW ALL BY THESE PRESENTS,  that the undersigned hereby authorizes Andrew
Ashe, of Applied Genetic Technologies  Corporation  (the "Company"), and Hemmie
Chang and Stacie Aarestad, each of Foley Hoag LLP, each acting singly, to
execute for and on behalf of the undersigned,  in the undersigned's capacity as
an officer of the Company,  a Form ID, Forms 3, 4 and 5, and any amendments
thereto, and cause such form(s) to be filed with the United States Securities
and Exchange Commission pursuant to Section 16(a) of the Securities  Act of
1934, relating to the undersigned's beneficial ownership of securities  in the
Company.  The undersigned hereby grants to the attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned  might
or could do personally present, with full power of substitution,  resubstitution
or revocation,  hereby ratifying and confirming all that such attorney-in-fact,
or such attorney's-in-fact substitute or substitutes,  shall lawfully do or
cause to be done by virtue of this power of attorney and the rights and powers
herein granted. The undersigned  acknowledges that the foregoing attorney-in-
fact, in serving in such capacity at the request of the undersigned,  is not
assuming,  nor is the Company assuming, any of the undersigned's
responsibilities to comply with Section 16 of the Securities  Exchange Act of
1934.

     This Power of Attorney shall remain in full force and effect until the
undersigned  is no longer required to file Forms 3, 4 and 5 with respect to the
undersigned's holdings of, and transactions  in, securities issued by the
Company,  unless earlier revoked by the undersigned  in a signed writing
delivered to the foregoing attorney-in-fact.

     IN WITNESS WHEREOF, the undersigned has caused this Power of. Attorney to
be executed as of this 13th day of SEPT, 2017.


                                            /s/ Matthew Feinsod
                                            -------------------------
                                            Matthew Feinsod